Antidepressant Activation: Why a Medication Can Make You Feel Worse at First.
By Julie Brownley, MD, PhD
Founder, Psychiatry for Women
A patient starts an antidepressant and calls three days later: “I thought this was supposed to help my anxiety. Why do I feel more anxious?”
Sometimes the answer is activation. It can feel like being unusually keyed up, restless, irritable, or unable to sleep. Some people describe a surge of anxiety or panic. Others say they feel physically uncomfortable in a way they can’t quite name. It may appear shortly after starting an antidepressant or raising the dose, well before there has been enough time to judge whether the medication will help the underlying condition.
The name sounds more precise than the science is. Researchers have also called this anxiety syndrome, and studies have used different definitions. A systematic review found reported rates ranging from 4% to 65%, a spread so wide that it tells us more about inconsistent measurement than about any one person’s odds. In one prospective outpatient study, about 7% developed symptoms within the first month; among those affected, the average onset was about seven days. [1, 2] In my clinical experience, this is a late estimate. Often, syndromal activation begins as early as 48 hours later.
This is one reason I ask what changed, when it changed, and what the experience actually feels like. “I’m anxious” might mean racing thoughts and worry. It might mean a body that feels agitated even when the person isn’t worrying about anything. It might mean someone has barely slept for four nights and is becoming unusually impulsive. Those are different clinical problems, even if they arrive in the same message to the prescriber.
This is what makes early “activation” tricky: it describes a set of symptoms, not a diagnosis. A person who says “I feel wired” might be having a temporary reaction to starting the medication, worsening anxiety, akathisia, or the beginning of hypomania or mania. Those can look similar at first, but they call for different responses.
Akathisia is a particularly distressing sense of inner restlessness, often with an urge to keep moving. Someone may pace or feel unable to sit still. That deserves assessment, not reassurance to “push through.” Antidepressants can cause akathisia, but we don’t have a dependable estimate of how often it happens. That uncertainty is another reason to ask specifically about the urge to move and the quality of the restlessness, rather than calling every early ‘wired’ feeling activation. In my clincial experience, akathisia in response to antidepressants is an infrequent occurence. Nonetheless, it's worth considering.
Hypomania or mania often appears with a different pattern: needing much less sleep without feeling tired, unusually high energy, increased confidence, racing thoughts, or behavior that is out of character. Feeling wired after a new medication does not, by itself, establish bipolar disorder. But if the pattern is escalating, we need to take a closer look. [3, 4]
I also see a version of this that catches people off guard. They took an antidepressant for years, did well, and eventually stopped it because they were doing well. When symptoms return, restarting the same medication seems like the obvious choice. But this time, even a familiar dose makes them feel like they are jumping out of their skin. They understandably ask, “How can I suddenly be unable to tolerate something that worked for me?”
My answer is that the medication is familiar, but the person is taking it in a different setting. Their baseline level of arousal may be much higher now. They may be sleeping badly, living through a different kind of stress, or navigating a different hormonal environment. Even the season and the pattern of symptoms that brought them back to treatment may have changed. Sleep loss can increase anxious arousal, and reproductive hormone changes can affect mood vulnerability. We cannot reliably point to one of those factors and say it caused the new reaction. But prior success with a medication is not a guarantee that restarting it will feel the same. [6, 7]
In that situation, I don't assume the person has become “intolerant of antidepressants.” Sometimes the useful move is to stabilize sleep and the other factors driving their distress before trying again. Sometimes I choose a less activating antidepressant or start the old one at a genuinely tiny dose, increasing much more slowly than I otherwise would. In selected cases, I may use a mood-stabilizing medication to help settle things before reintroducing an antidepressant. That decision does not, on its own, mean I think the person has bipolar disorder. It means I'm treating the state they're in now while continuing to pay attention to the diagnosis. These are individualized clinical choices, not a proven formula for preventing activation.
Dose matters. In a prospective study of newer antidepressants, higher-dose treatment was associated with greater odds of jitteriness symptoms [5]. That does not mean everyone needs the smallest possible dose forever. It means the starting dose and pace of increases are real clinical decisions, especially for someone who has reacted strongly to medication before. If the symptoms are mild, brief, and improving, we may watch them closely. If they are disruptive, I may slow the titration, return to a prior dose, or reconsider the medication. There is no prize for enduring a dose that makes someone miserable.
There is also no good reason to assume every new symptom is caused by the prescription. I ask about caffeine, stimulants, other medication changes, missed doses, sleep loss, and what was happening before treatment began. Timing is a clue, not a diagnosis.
The safety piece matters. New suicidal thoughts, severe agitation, an inability to sleep, or marked changes in behavior warrant prompt contact with the prescriber. If someone feels at immediate risk of harming themselves, they need urgent help right away. Antidepressant labeling specifically calls for close monitoring early in treatment and around dose changes. It lists anxiety, agitation, insomnia, akathisia, and hypomania or mania among the changes clinicians should take seriously, while also acknowledging that a direct causal link between those symptoms and suicidal behavior has not been established. [3]
My approach is to tell patients what to watch for before they start, and make it easy to report it. An antidepressant can still be the right medication when the first week feels rough. But “give it time” is only useful advice after we understand what is happening and decide it is safe to give it time.
References
Sinclair LI, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. British Journal of Psychiatry. 2009;194:483–490. https://pubmed.ncbi.nlm.nih.gov/19478285/
Harada T, et al. A prospective naturalistic study of antidepressant-induced jitteriness/anxiety syndrome. Neuropsychiatric Disease and Treatment. 2014. https://pubmed.ncbi.nlm.nih.gov/25419134/
U.S. Food and Drug Administration. Aplenzin prescribing information, section 5.1. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022108s023lbl.pdf
Goldberg JF, Ernst CL. What to do when your depressed patient develops mania. Federal Practitioner. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC6375439/
Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors. Asian Journal of Psychiatry. 2017. https://pubmed.ncbi.nlm.nih.gov/29061415/
Babson KA, et al. A test of the effects of acute sleep deprivation on general and specific self-reported anxiety and depressive symptoms: an experimental extension. Journal of Behavior Therapy and Experimental Psychiatry. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC2862829/
Maki PM, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018. https://pubmed.ncbi.nlm.nih.gov/30179986/
About the Author
Julie Brownley, MD, PhD is a psychiatrist specializing in women’s mental health and the founder of Psychiatry for Women. Her work focuses on perinatal mental health, hormonal transitions, and helping women make thoughtful, individualized decisions about their care.
Continue exploring the latest at Psychiatry for Women
Comments